Available Brands
Did you find this information helpful?
Author Details
Written By
Vishishta
M.Sc Microbiology

Reviewed By
Dr. Tejashwin Adiga
MBBS
Last updated : 09 Oct 2026 | 10:36 AM (IST)

Want to know more?
Read Our Editorial Policy
Quick Summary
TENOFOVIR DISOPROXIL FUMARATE
Last updated on 09 Oct 2026 | 10:36 AM (IST)
TENOFOVIR DISOPROXIL FUMARATE
Molecule Overview
Tenofovir disoproxil fumarate (TDF) is an antiviral medicine used to treat both HIV infection and chronic hepatitis B, and to help prevent HIV infection in people at high risk. It belongs to a class of medicines called nucleotide reverse transcriptase inhibitors. It is a prescription-only medicine.
Medical Classification
Therapeutic Class: Antiviral medicine (antiretroviral / anti-hepatitis B agent).
Pharmacological Class: Nucleotide analog reverse transcriptase inhibitor.
Drug Family: Acyclic nucleotide phosphonates.
ATC Classification: J05AF07 (Tenofovir disoproxil).
Conditions Treated
Approved: HIV-1 infection, in combination with other antiretroviral agents, in adults and pediatric patients weighing at least 17 kg; chronic hepatitis B infection in adults and certain pediatric patients; and pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV in at-risk adults and adolescents, in combination with emtricitabine.
Commonly used for: People living with HIV as part of combination therapy, people with chronic hepatitis B needing antiviral suppression, and HIV-negative individuals at ongoing risk of HIV exposure using PrEP.
Off-label use (only under medical guidance): Not typically used off-label, given its broad approved indication set.
Available Strengths & Dosage Forms
● Oral tablets: 300 mg (standard adult strength), with lower pediatric strengths (e.g., 150 mg, 200 mg, 250 mg) available for weight-based dosing.
● Oral powder: for younger children unable to take tablets, dosed by body weight.
How the Molecule Works
Tenofovir disoproxil fumarate is a prodrug that is converted in the body to its active form, tenofovir. Tenofovir then acts as a faulty building block that HIV or hepatitis B virus mistakenly incorporates while trying to copy its genetic material, which stops the viral reverse transcriptase enzyme from completing this process, halting viral replication.
Dosage & Administration
Standard dose (HIV or hepatitis B treatment): 300 mg once daily, with or without food.
Condition-wise dose (PrEP): 300 mg once daily, combined with emtricitabine, taken consistently for ongoing HIV prevention in at-risk individuals.
Route: Oral, once daily.
Renal impairment: Dose interval is adjusted (e.g., every 48 hours or longer) based on creatinine clearance in patients with reduced kidney function.
Missed dose: Take as soon as remembered unless close to the next dose; don't double up.
Overdose: May increase the risk of kidney-related side effects; requires medical attention.
Side Effects
Common: Nausea, diarrhoea, and headache.
Serious: Kidney function decline (including rare cases of kidney failure), reduced bone mineral density, and lactic acidosis (a rare but serious buildup of lactic acid) with severe hepatomegaly.
Emergency symptoms: Decreased urination, unusual muscle pain or weakness, rapid breathing, or unusual tiredness (possible signs of lactic acidosis or kidney problems).
Recovery advice: Kidney function and bone density are monitored proactively, since problems are often identified through routine tests before symptoms appear; staying well hydrated supports kidney health during treatment.
Warnings & Precautions
Pregnancy: Used when clearly needed, including as part of standard HIV treatment regimens during pregnancy, under medical guidance.
Breastfeeding: Discussed with the treating doctor, in line with broader HIV/hepatitis B and breastfeeding guidance.
Liver disease: Used with monitoring, particularly given the hepatitis B flare risk on discontinuation.
Kidney disease: Requires dose interval adjustment based on kidney function; not recommended in some cases of severe impairment without careful monitoring.
Elderly: Used with caution given higher likelihood of reduced kidney function in this age group.
Children: Approved from 17 kg body weight and above for HIV treatment, and in certain pediatric hepatitis B settings, with weight-based dosing.
Drug Interactions
● Other nephrotoxic drugs (e.g., NSAIDs, aminoglycosides, certain antivirals): increases the risk of kidney effects when combined.
● Didanosine: coadministration with tenofovir DF increases didanosine levels and toxicity risk; generally avoided.
● Atazanavir and certain other HIV protease inhibitors: tenofovir DF can reduce their levels, sometimes requiring a booster (ritonavir) or dose adjustment.
● Other tenofovir-containing products: should not be combined to avoid duplicate dosing.
Monitoring Requirements
● Kidney function tests (serum creatinine, estimated creatinine clearance) before starting and periodically during treatment.
● Hepatitis B virus testing before starting, and hepatic function monitoring if the medicine is discontinued in coinfected patients.
● Bone density assessment in patients with a history of fracture or other bone loss risk factors.
● HIV viral load and CD4 count (for HIV treatment) or hepatitis B viral markers (for HBV treatment) to monitor response.
Alternative Molecules
Tenofovir alafenamide (a newer prodrug with reduced kidney/bone effects), Entecavir (for hepatitis B specifically), other nucleos(t)ide reverse transcriptase inhibitors.
Combination Therapies
Used in combination with emtricitabine (for both HIV treatment and PrEP) and with other antiretroviral classes for full HIV suppression; used alone or alongside other agents for chronic hepatitis B, depending on the clinical situation.
● HIV / Antiretroviral Medicines
● Hepatitis B Medicines
● HIV Pre-Exposure Prophylaxis (PrEP)
FAQs
Q1.
It's used to treat HIV-1 infection (as part of combination therapy), to treat chronic hepatitis B, and for HIV pre-exposure prophylaxis (PrEP) in at-risk individuals.
Q2.
It can affect kidney function over time in some people, which is why regular kidney function monitoring is part of standard care while on this medicine.
Q3.
No, they are related but distinct prodrugs of the same active molecule (tenofovir); tenofovir alafenamide is dosed lower and generally has less impact on kidney function and bone density.
Q4.
Because stopping this medicine in someone coinfected with hepatitis B can trigger a serious flare-up of hepatitis B, so testing and monitoring are important.
Q5.
Yes, combined with emtricitabine, it's approved as PrEP for people at ongoing risk of HIV exposure, taken consistently as prescribed.
References
Disclaimer
The information on this page is for educational purposes only and is not a substitute for medical advice. Please consult your doctor to know if this treatment is appropriate for your condition.






